2[2]Livermore DM. Determinants of the activity of heta-lactamase inhibitor combinations [ J]. J Antimicrob Chemother, 1993,31(Supp1 A) :9-21
3[3]Fritsche TR, Sader HS, Jones RN, et al. Comparative activity and sectrum of broad-spectrum β-lactams (cefepime, ceftazidime, ceftriaxone, piperacillin/tazobactam) tested against 12,295 staphylococci and streptococci: report from the SENTRY antimicrobial surveillance program(North America: 2001-2002)[J]. Diagn Microbiol Infect Dis, 2003,47:435-440
4[4]Karlowsky JA, Weaver MK, Thornsberry C, et al. C. omparison of four antimicrobial susceptibility testing methods to determine the in vitro antivities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa[J]. J Clin Microbio. 2003,41:3339-3343
6[6]Jonew RN,Kirby JT,Beach ML, et al. Geographic variations in activity of broad-spectrum-bata-lactams against Pseudomonas aeruginosa:summary of the worldwide SENTRY Antimicrobial Surveillance Program(1997-2000) [J]. Diagn Microbiol Infect Dis, 2002,43: 239-243
7[7]Aldridge KE, Ashcraft D, Cambre K, et al. Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, prevotella, Fusobacterium,porphyromonas,and peptostrptococcus species[J]. Antimicrob Agents Chemother. 2001,45:1238-1243
8[8]Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1197-2000[J]. Clin Infect Dis. 2002,35(Suppl 1) :S126-134
9[9]Platsouka E,Zissis NP,Portolos J, et al. Bacterial susceptibilities to piperacillin-tazobaetam in a tertiary care hospital: 5-year review[J]. J Chemother. 2003 , 15:27-30
10[10]Livermore DM,Mushtaq S,James D, et al. In vitro activety of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalized patients in the British Isles[J].Int J Antimicrob Agents. 2003,22:14-27
二级参考文献12
1Bergogne-Berezin E. Guideline on antimicrobial chemotherapy for prevention and treatment of infections in the ICU. J Chemother, 2001,1: 134-149.
2Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis, 2001, 41: 183-189.
3Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in gram-negative isolates from ICU in Turkey:analysis of data from the last 5 years. J Chemother, 2002, 14:140-146.
4Karlowsky JA, Kelly LJ, Thornsberry C , et al. Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000:TRUST and TSN data for the United States. J Autimicrob Agents , 2002,19: 21-31.
5National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Approved standard M100-S12. National Committee for Clinical Laboratory Standards,Wayne, Pa.2002,1.
6Chanawong A. M' Zali FH, Heritage J, et al. Three cefotaximases,CTX-M-9, CTX-M-13, CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother, 2002, 46:630-637.
